These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

691 related items for PubMed ID: 19446316

  • 1. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients.
    Eitan R, Kushnir M, Lithwick-Yanai G, David MB, Hoshen M, Glezerman M, Hod M, Sabah G, Rosenwald S, Levavi H.
    Gynecol Oncol; 2009 Aug; 114(2):253-9. PubMed ID: 19446316
    [Abstract] [Full Text] [Related]

  • 2. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
    Landrum LM, Moore KN, Myers TK, Lanneau GS, McMeekin DS, Walker JL, Gold MA.
    Gynecol Oncol; 2009 Feb; 112(2):337-41. PubMed ID: 19041126
    [Abstract] [Full Text] [Related]

  • 3. Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel.
    Su D, Smith SM, Preti M, Schwartz P, Rutherford TJ, Menato G, Danese S, Ma S, Yu H, Katsaros D.
    Cancer; 2009 Jun 01; 115(11):2453-63. PubMed ID: 19322891
    [Abstract] [Full Text] [Related]

  • 4. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer.
    Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Aghajanian C, Barakat RR, Chi DS.
    Gynecol Oncol; 2008 Feb 01; 108(2):276-81. PubMed ID: 18063020
    [Abstract] [Full Text] [Related]

  • 5. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
    Pectasides D, Fountzilas G, Aravantinos G, Kalofonos C, Efstathiou H, Farmakis D, Skarlos D, Pavlidis N, Economopoulos T, Dimopoulos MA.
    Gynecol Oncol; 2006 Aug 01; 102(2):285-91. PubMed ID: 16516283
    [Abstract] [Full Text] [Related]

  • 6. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
    Juretzka MM, Barakat RR, Chi DS, Iasonos A, Dupont J, Abu-Rustum NR, Poynor EA, Aghajanian C, Spriggs D, Hensley ML, Sabbatini P.
    Gynecol Oncol; 2007 Jan 01; 104(1):176-80. PubMed ID: 16996584
    [Abstract] [Full Text] [Related]

  • 7. Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
    Pectasides D, Fountzilas G, Aravantinos G, Kalofonos HP, Efstathiou E, Salamalekis E, Farmakis D, Skarlos D, Briasoulis E, Economopoulos T, Dimopoulos MA.
    Gynecol Oncol; 2005 May 01; 97(2):436-41. PubMed ID: 15863142
    [Abstract] [Full Text] [Related]

  • 8. Survival among patients with platinum resistant, locally advanced non-small cell lung cancer treated with platinum-based systemic therapy.
    d'Amato TA, Pettiford BL, Schuchert MJ, Parker R, Ricketts WA, Luketich JD, Landreneau RJ.
    Ann Surg Oncol; 2009 Oct 01; 16(10):2848-55. PubMed ID: 19609620
    [Abstract] [Full Text] [Related]

  • 9. Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients.
    Chen YJ, Yuan CC, Chow KC, Wang PH, Lai CR, Yen MS, Wang LS.
    Gynecol Oncol; 2005 Apr 01; 97(1):110-7. PubMed ID: 15790446
    [Abstract] [Full Text] [Related]

  • 10. Carcinosarcoma of the ovary treated with platinum and taxane: the memorial Sloan-Kettering Cancer Center experience.
    Leiser AL, Chi DS, Ishill NM, Tew WP.
    Gynecol Oncol; 2007 Jun 01; 105(3):657-61. PubMed ID: 17395252
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
    Cicin I, Saip P, Eralp Y, Selam M, Topuz S, Ozluk Y, Aydin Y, Topuz E.
    Gynecol Oncol; 2008 Jan 01; 108(1):136-40. PubMed ID: 17936342
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy.
    Darcy KM, Tian C, Reed E.
    Cancer Res; 2007 May 01; 67(9):4474-81. PubMed ID: 17483363
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy.
    Kelly MG, O'malley DM, Hui P, McAlpine J, Yu H, Rutherford TJ, Azodi M, Schwartz PE.
    Gynecol Oncol; 2005 Sep 01; 98(3):353-9. PubMed ID: 16005947
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.